Omnisense is the ONLY QUS device that enables measurement at multiple skeletal sites. This advantage provides the physician with higher sensitivity, improved confidence in fracture discrimination, improved monitoring ability, and better measurement flexibility vs. QUS heel systems.

Omnisense's T-score corresponds well with DXA T-scores at the spine and forearm, crossing the -2.5 threshold at the same age point. This demonstrates the applicability of WHO criteria for diagnosis with Omnisense.

Omnisense has the best precision level in the QUS market, between 0.4% - 0.81%, depending on skeletal site.
· Omnisense precision at the radius is 0.4%.
· DXA precision: 2-3%.
· Other QUS devices sold in the U.S.: 1.48% (Sahara), 2.0% (Achilles), 4.0% (Cuba).

A lower measurement error (precision level) indicates a better monitoring capability.

The high sensitivity of Omnisense enables it to detect the smaller changes that take place at the radius, a skeletal site that includes mostly cortical bone.

Omnisense is approved for use in the U.S. in monitoring changes in bone due to aging and treatment. Clinical studies have demonstrated its ability to detect the effects of both HRT and Alendronate (Fosamax) on bone.

Omnipath technology measures SOS along the bone, providing an accurate measure of bone, without the surrounding soft tissue. Heel QUS devices measure the soft tissue across the bone, providing measurement results that are less accurate and less precise.

The radius (forearm) is an excellent skeletal site for bone strength assessment:
· It is one of the three major osteoporotic fracture sites, generally the first site to fracture at an earlier age.
· It differentiates between non-fractured subjects and subjects with any osteoporotic fracture and predicts fracture risk.
· The heel, the skeletal site measured by most other QUS devices, is not a fracture site.

Omnisense provides a clearly printed, easy-to-read 8.5" by 11" report with T-and Z-score values. Other QUS devices provide a narrow-slip report. On the Omnisense measurement report, current and past results are depicted on the same colored graph for quick detection of a trend in bone strength. Any existing office printer can be hooked up to Omnisense for printout, or results can be viewed on-screen.

Omnisense Report

Achilles Report

Only Omnisense has a built-in male reference database as part of the system. All other approved QUS devices in the U.S. use female norms to calculate Z-scores for bone measurement in men.

Omnisense is the only QUS device on the market that incorporates a PC in its basic configuration, providing a detailed, high-level, color graphic user interface. Unlike competing products, it does not require connection to an external computer for on-screen viewing of results. The device fits into a suitcase for easy transport.

Omnisense has been studied in over 200 abstracts and 20 full papers over six years of use in research and four years of clinical use. This is an unprecedented rate of publications relative to sales duration.

Omnisense's worldwide installed base is nearly 2000 units within only four years of sales!

This positions SUNLIGHT as a market leader in QUS annual sales for the past two years, with an excellent reputation and high brand recognition.